Loading asset research
Q2 2026 earnings · Sep 28
Psyence Biomedical Ltd. Common Shares
PBMNasdaq · USD · StocksQuote as of · Exchange session not verified$5.86
-7.13%
Today
PBM
Loading 1D prices…
Market cap
$21.6M
Volume
137.5K
52w high
$175.7852w low
$1.92Company profile
Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
TORONTO, United States
Employees
12
Fiscal year end
0331
CIK
1985062
Session & valuation
Open$6.19
Previous close$6.31
Day high$6.37
Day low$5.61
30-day avg. volume102K
Outstanding shares2.3M
Diluted EPS$32.76
Latest annual period
P/E (trailing)0.18
P/E (forward)—
Price / book0.77
Beta1.73
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| COCPCocrystal Pharma Inc. Common Stock | $22.2M | $0.00 | — | -$0.78 | -3.36% | Buy |
| NXTCNextCure Inc. Common Stock | $23.3M | $0.00 | — | -$19.65 | +9.54% | Buy |
| ATOSAtossa Therapeutics Inc. Common Stock | $20M | $0.00 | — | -$4.04 | -5.96% | Buy |
| NEUPNeuphoria Therapeutics Inc. Common Stock | $19.9M | $1.2M | -1145.66% | -$3.06 | -0.82% | Hold |
| TXMDTherapeuticsMD Inc. Common Stock | $23.6M | $3M | -18.83% | -$0.05 | -1.84% | Unrated |